PRINCETON, N.J., March 27, 2012 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Lisa Cozza as Vice President, Business Development and member of the Management Committee.
(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )
Ms. Cozza will report directly to Michael A. Griffith, Chief Executive Officer. “Lisa is highly regarded in the industry and is a welcome addition to the Laureate team,” said Michael Griffith. “Her strong process development and technology manufacturing experience, coupled with an entrepreneurial spirit, make Lisa the ideal choice to lead this area of our organization and continue to grow our business.” Ms. Cozza has over 25 years of business development and operations experience in biopharmaceutical process development, quality, clinical laboratory sciences and manufacturing. Prior to this appointment, Lisa distinguished herself as Executive Director of Manufacturing Alliances at Human Genome Sciences where she successfully implemented a contract manufacturing enterprise.
Ms. Cozza spent nine years at Lonza Biologics, where she was director of Commercial and Clinical manufacturing, training and process technology teams. Before joining Lonza, Lisa spent seven years with Genetics Institute (now Pfizer) in various tactical and lead roles in quality control, purification process development and the clinical manufacturing areas. Ms. Cozza earned a B.S. in Medical Technology from the University of Massachusetts and spent 8 years working in clinical hematology, microbiology, and chemistry labs. She later received an MBA from Northeastern University, Boston, MA.
About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma’s scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, the company’s portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981, and is a portfolio company of Saints Capital, LLC. For more information, please visit www.LBioS.com.
About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and, in special situations, in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies.
For more information, please visit www.saintsvc.com.
For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367, or info@LBioS.com or visit www.LBioS.com.
SOURCE Laureate Biopharmaceutical Services, Inc.
